Cibc World Markets Corp Purchases 3,765 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Cibc World Markets Corp boosted its position in Charles River Laboratories International, Inc. (NYSE:CRLFree Report) by 133.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,595 shares of the medical research company’s stock after acquiring an additional 3,765 shares during the quarter. Cibc World Markets Corp’s holdings in Charles River Laboratories International were worth $1,559,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of CRL. VisionPoint Advisory Group LLC grew its stake in shares of Charles River Laboratories International by 105.7% during the third quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company’s stock worth $28,000 after buying an additional 74 shares during the last quarter. Headlands Technologies LLC acquired a new position in shares of Charles River Laboratories International during the third quarter worth $37,000. Operose Advisors LLC acquired a new position in shares of Charles River Laboratories International during the third quarter worth $42,000. Brown Brothers Harriman & Co. lifted its holdings in shares of Charles River Laboratories International by 76.0% during the fourth quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical research company’s stock worth $52,000 after purchasing an additional 95 shares during the period. Finally, Provence Wealth Management Group acquired a new position in shares of Charles River Laboratories International during the third quarter worth $57,000. Institutional investors own 98.91% of the company’s stock.

Insider Transactions at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 1,304 shares of the business’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $226.97, for a total transaction of $295,968.88. Following the completion of the sale, the executive vice president now directly owns 23,276 shares of the company’s stock, valued at $5,282,953.72. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Trading Down 0.1 %

NYSE:CRL opened at $214.51 on Tuesday. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.75 and a quick ratio of 1.37. The firm has a 50-day moving average of $231.10 and a 200-day moving average of $231.84. The company has a market cap of $11.05 billion, a PE ratio of 25.24, a PEG ratio of 2.03 and a beta of 1.40. Charles River Laboratories International, Inc. has a one year low of $161.65 and a one year high of $275.00.

Charles River Laboratories International (NYSE:CRLGet Free Report) last posted its earnings results on Thursday, May 9th. The medical research company reported $2.27 EPS for the quarter, topping the consensus estimate of $2.05 by $0.22. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $997.24 million. Charles River Laboratories International had a net margin of 10.81% and a return on equity of 15.16%. As a group, equities research analysts expect that Charles River Laboratories International, Inc. will post 11 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

CRL has been the topic of a number of recent research reports. TD Cowen cut their price target on shares of Charles River Laboratories International from $260.00 to $228.00 and set a “hold” rating on the stock in a report on Monday, May 13th. Guggenheim lowered shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating in a report on Thursday, February 15th. Evercore ISI lifted their price target on shares of Charles River Laboratories International from $260.00 to $265.00 and gave the stock an “outperform” rating in a report on Thursday, February 15th. Argus boosted their target price on shares of Charles River Laboratories International from $240.00 to $290.00 and gave the company a “buy” rating in a report on Monday, March 18th. Finally, Citigroup boosted their target price on shares of Charles River Laboratories International from $215.00 to $250.00 and gave the company a “neutral” rating in a report on Thursday, February 15th. Five analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $256.38.

View Our Latest Research Report on CRL

Charles River Laboratories International Company Profile

(Free Report)

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Featured Stories

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.